Mr. Cameron Groome reports

MICROBIX ANNOUNCES ANNUAL AND SPECIAL MEETING VOTING RESULTS

Microbix Biosystems Inc. has released the voting results from the annual and special meeting of shareholders of the company held on March 26, 2025.

At the meeting, 42.83 per cent of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. Details of all resolutions that were voted upon are set out in the management information circular dated Feb. 7, 2024. The circular is available on the company's website and on SEDAR+.

All board of directors nominees listed in the circular were re-elected as directors of Microbix. Results of the vote are provided in an attached table.

Shareholders also approved a resolution reappointing the company's auditor, Ernst & Young LLP, with 99.92 per cent of the votes cast in favour.

The slides of management's presentation at the meeting have been posted at the Microbix website.

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 120 skilled employees and annualized sales targeting $2-million or more per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, United States Food and Drug Administration registered, Australian Therapeutic Goods Administration registered and Health Canada licensed, and provides IVDR-compliant (in vitro diagnostic regulation), CE-marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (such as DxTM for patient-sample collection). Microbix is headquartered in Mississauga, Ont., Canada.

We seek Safe Harbor.